ARA-290

ARA-290 is one of the more elegantly designed peptides on this list, with mechanistic depth far in excess of its commercial-development trajectory. The clinical-trial program developed by Araim Pharmaceuticals — co-founded by Anthony Cerami (long-time EPO biology investigator) and Michael Brines — concentrated on small-fiber neuropathy associated with sarcoidosis and on diabetic peripheral neuropathy, both conditions where the underlying biology features chronic neuroinflammation, microvascular compromise, and intraepidermal nerve fiber loss that the IRR-mediated tissue-protective mechanism plausibly addresses.

The sarcoidosis evidence arc begins with a 22-patient double-blind randomized pilot study, Heij, Niesters, Swartjes et al., Mol Med 2012, 18:1430–1436, in which intravenous ARA-290 at 2 mg three times weekly for four weeks produced a statistically significant improvement in the Small Fiber Neuropathy Screening List (SFNSL) score versus placebo, with 42% of the active-arm recipients showing a ≥15-point SFNSL improvement against zero in placebo and a clean tolerability profile. The follow-up Phase II, Dahan, Dunne, Swartjes et al., Mol Med 2013, 19:334–345, used 28-day daily subcutaneous dosing in patients with documented small-nerve-fiber loss from sarcoidosis and reported significant improvement in neuropathic symptoms versus placebo, a statistically significant increase in corneal small-nerve-fiber density, improved thermal pain thresholds (cold p=0.027; hot p=0.032), enhanced thermal discrimination (p=0.008), and increased six-minute walk distance — with sustained signal through a 16-week follow-up. The most rigorous trial in the program is the Phase IIb, multicenter, dose-finding RCT Culver, Dahan, Bajorunas et al., Invest Ophthalmol Vis Sci 2017, 58:BIO52–BIO60: 64 patients with sarcoid-associated small-nerve-fiber loss randomized across placebo and three cibinetide doses (1, 4, 8 mg/day subcutaneous, 28 days). The 4-mg arm met the prespecified primary endpoint of change in corneal nerve fiber area at day 28 (placebo-corrected mean change 697 μm², p=0.012), with parallel significant gains in GAP-43-positive regenerating intraepidermal nerve fibers (p=0.035) and correlation of corneal nerve regeneration with six-minute-walk improvement (ρ=0.645, p=0.009). The intermediate review van Velzen, Heij, Niesters et al., Expert Opin Investig Drugs 2014, 23:541–550 frames the sarcoidosis program through the 2013 trial; the Dahan, Brines, Niesters et al., Pain Rep 2016, 1:e566 review extends the picture across the sarcoidosis and diabetic-neuropathy arms.

The diabetic peripheral neuropathy arm is anchored by Brines, Dunne, van Velzen et al., Mol Med 2015, 20:658–666, a 48-patient (24 per arm) double-blind placebo-controlled Phase II trial in type 2 diabetes with painful distal neuropathy. The trial reported a small but statistically significant HbA1c reduction in the cibinetide arm (−0.21% vs +0.21% placebo at day 56, p=0.002), an improvement in PainDetect scores (3.3 vs 1.1 points, p=0.037), and an increase in corneal nerve fiber density in subjects whose baseline density was more than one standard deviation below normal (+2.6 vs +0.7 fibers/mm², p=0.02), with no clinically significant safety signals. The metabolic effect is a notable observation in its own right — cibinetide is not designed as a glycemic agent — and is consistent with the broader IRR-mediated anti-inflammatory framing, where chronic low-grade tissue inflammation contributes to insulin resistance.

Three boundaries on this story matter, all three addressed below rather than only the comfortable one. First, the sarcoidosis and diabetic-neuropathy trials are Phase II in scale (n=22, n=48, n=64) and short in duration (28-day primary endpoints, 16-week extended follow-up at most). The signals are real and the corneal-confocal-microscopy and intraepidermal-nerve-fiber endpoints are mechanistically informative, but Phase II is not Phase III, and no pivotal trial in any indication has completed. Second, the development program has stalled commercially since the mid-to-late 2010s. The 2017 Phase IIb readout was paired with a successful FDA end-of-Phase-II meeting and the expectation of further trials; the program did not progress to Phase III for any indication, and Araim Pharmaceuticals' clinical-development activity has not produced new pivotal-trial readouts since. The stalling is attributable to commercial and organizational factors rather than to any published safety signal or regulatory rejection — the molecule is in clinical-development limbo, not in a documented failure mode. Third, the gray-market self-experimentation use that has developed around cibinetide is broader than the trial-supported indications: subcutaneous ARA-290 is reported anecdotally for neuropathic pain of various etiologies, including post-COVID neuropathy / dysautonomia and idiopathic small-fiber neuropathy, but the peer-reviewed literature does not extend to those indications, and the sample sizes and follow-up durations in the published trials do not yet support general efficacy claims even for the indications studied.

The molecule sits at an unusual point in the corpus: real receptor-pharmacology depth, real Phase II signal across two distinct neuropathic conditions, no progression to Phase III. Comparators within the immune-modulating peptide class — particularly Thymosin α-1, which has a 35-country regulatory footprint built on chronic hepatitis evidence — frame the contrast: cibinetide has the more elegantly designed receptor biology and a thinner regulatory record. The healing and angiogenesis dossier and BPC-157 discussion provide the broader tissue-repair-via-vascular-recruitment context that is mechanistically adjacent but pharmacologically distinct from the IRR-mediated repair program.